Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)
Public ClinicalTrials.gov record NCT01313208. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Subjects With Moderately Active Rheumatoid Arthritis Despite DMARD Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to evaluate the effectiveness of adding etanercept to disease modifying anti-rheumatic drug (DMARD) therapy in patients with moderately active Rheumatoid Arthritis (RA).
Study identification
- NCT ID
- NCT01313208
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 210 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2011
- Primary completion
- Jan 31, 2013
- Completion
- Apr 30, 2013
- Last update posted
- Feb 8, 2017
2011 – 2013
United States locations
- U.S. sites
- 38
- U.S. states
- 20
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35205 | — |
| Research Site | Tuscaloosa | Alabama | 35406 | — |
| Research Site | Peoria | Arizona | 85381 | — |
| Research Site | Scottsdale | Arizona | 85258 | — |
| Research Site | Encino | California | 91436 | — |
| Research Site | Hemet | California | 92543 | — |
| Research Site | Inglewood | California | 90301 | — |
| Research Site | La Jolla | California | 92037 | — |
| Research Site | Murrieta | California | 92563 | — |
| Research Site | Santa Maria | California | 93454 | — |
| Research Site | Tustin | California | 92780 | — |
| Research Site | Upland | California | 91786 | — |
| Research Site | Victorville | California | 92395 | — |
| Research Site | Denver | Colorado | 80230 | — |
| Research Site | Jacksonville | Florida | 32209 | — |
| Research Site | Ocala | Florida | 34474 | — |
| Research Site | Sarasota | Florida | 34239 | — |
| Research Site | Sebring | Florida | 33870 | — |
| Research Site | Tampa | Florida | 33613 | — |
| Research Site | Atlanta | Georgia | 30342 | — |
| Research Site | Meridian | Idaho | 83642 | — |
| Research Site | Springfield | Illinois | 62704 | — |
| Research Site | Lexington | Kentucky | 40504 | — |
| Research Site | Frederick | Maryland | 21702 | — |
| Research Site | Lansing | Michigan | 48910 | — |
| Research Site | Saint Clair Shores | Michigan | 48081 | — |
| Research Site | Bismarck | North Dakota | 58501 | — |
| Research Site | Akron | Ohio | 44311 | — |
| Research Site | Mayfield Village | Ohio | 44143 | — |
| Research Site | Oklahoma City | Oklahoma | 73103 | — |
| Research Site | Oklahoma City | Oklahoma | 73109 | — |
| Research Site | Portland | Oregon | 97239 | — |
| Research Site | Erie | Pennsylvania | 16508 | — |
| Research Site | Greer | South Carolina | 29650 | — |
| Research Site | Dallas | Texas | 75231 | — |
| Research Site | San Antonio | Texas | 78232 | — |
| Research Site | Chesapeake | Virginia | 23320 | — |
| Research Site | Seattle | Washington | 98133 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
Recently updated Rheumatoid Arthritis trials
Other public records listing Rheumatoid Arthritis. Sorted by last update posted; newest first. Not a recommendation.
- NCT07137598: A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) Recruiting
- NCT04817969: Persona Ti-Nidium Post-Market Clinical Follow-up Active, not recruiting
- NCT07620392: An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis Recruiting
- NCT05936970: Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD Active, not recruiting
- NCT07704580: Phase 1b/2 Study of IV Sarilumab in Adult With RA Recruiting
- NCT07293871: Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01313208, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 8, 2017 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01313208 live on ClinicalTrials.gov.